NEW YORK (GenomeWeb) – Cell detection and liquid biopsy firm RareCyte said today that it has raised $30 million in a private financing round, which it plans to use to advance commercial sales efforts and build new companion diagnostic partnerships.

The investment was led by 5AM Ventures with additional participation from existing investors including Telegraph Hill Partners.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.